Table 2.
Overview of exposure-survival analysis outcomes
| Renal cell carcinoma | Soft tissue sarcoma | Overall | |
|---|---|---|---|
| Patients (n) | 35 | 26 | 61 |
| Median PFS (weeks) | 29.9 | 18.3 | 24.4 |
| Median PFS Cmin > 20 mg/L (weeks) | 34.1 | 18.7 | 25.0 |
| Median PFS Cmin < 20 mg/L (weeks) | 12.5 | 8.8 | 8.8 |
| Univariate p value (log-rank test) | 0.027 | 0.142 | 0.012 |
| Hazard ratio (95% CI)* | 0.25 (0.076–0.81) | 0.12 (0.024–0.61) | 0.38 (0.17–0.92) |
| Multivariate p value (Cox regression) | 0.021 | 0.011 | 0.017 |
C min pazopanib trough level/minimum plasma concentration
PFS progression free survival
95% CI 95% confidence interval
*Hazard ratios are based on the multivariate Cox regression analysis